Avidity Biosciences, Inc. (RNA)

Market Cap	3.80B
Revenue (ttm)	10.12M
Net Income (ttm)	-280.49M
Shares Out	119.31M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,497,641
Open	30.92
Previous Close	31.05
Day's Range	30.85 - 32.63
52-Week Range	8.86 - 56.00
Beta	0.89
Analysts	Strong Buy
Price Target	64.36 (+102.26%)
Earnings Date	Nov 7, 2024

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial;...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 253
• Stock Exchange: NASDAQ
• Ticker Symbol: RNA
• Website: https://www.aviditybiosciences.com

Financial Performance

In 2023, Avidity Biosciences's revenue was $9.56 million, an increase of 3.64% compared to the previous year's $9.22 million. Losses were -$212.22 million, 22.0% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is $64.36, which is an increase of 102.26% from the latest price.

Price Target

$64.36

(102.26% upside)

Analyst Consensus: Strong Buy